Shaping the Future of Richter Transformation: Foundations, Evidence, and the Role of Bispecific Antibodies

Dr. Kittai is an Associate Professor at the Icahn School of Medicine at Mount Sinai in New York, NY where he is the Assistant Director of Lymphoma Clinical Research and chronic lymphocytic leukemia (CLL) Clinical Research Leader. His clinical and research focus is on CLL, Richter transformation and related disorders. He is the primary investigator of multiple investigator-initiated trials exploring the use of small molecule inhibitors with novel designs and deploying cellular therapies for CLL and Richter transformation. Dr. Kittai is also interested in re-defining prognostic features for patients with CLL in the era of targeted therapies, as well as defining and mitigating racial disparities that exist in CLL. He has been the recipient of multiple teaching awards and is an active member of the American Society of Hematology Committee on Training. ACTIVITY AFFILIATIONS January 15, 2026 Shaping the Future of Richter Transformation: Foundations, Evidence, and the Role of Bispecific Antibodies March 10, 2025 Overcoming Barriers That Inhibit Optimal Adherence, Persistence, and Tolerability to Oral CLL Therapies

Mazyar Shadman, MD, MPH, is the Innovators Network Endowed Chair and a Professor at Fred Hutchinson Cancer Center (Fred Hutch) and the University of Washington (UW) in Seattle. He is also the Medical Director for Cellular Immunotherapy and Bezos Family Immunotherapy Clinic, and the interim Deputy Chief Medical Officer at the Fred Hutch. He is a hematologic malignancies expert who specializes in treating patients with lymphoma/CLL. He is involved in clinical trials using novel therapeutic agents, cellular immunotherapy (CAR-T cell), and stem cell transplant for treatment of lymphoid malignancies. He also studies the clinical outcomes of patients using institutional and collaborative retrospective cohort studies. Dr. Shadman received his MD from Tehran University in Iran. He finished internal medicine internship and residency training at the Cleveland Clinic in Cleveland, Ohio and completed his training in hematology and medical oncology fellowships at the UW and Fred Hutch. Dr. Shadman also earned an MPH degree from UW and was a fellow for the National Cancer Institute’s cancer research training program at Fred Hutch, where he studies cancer epidemiology.